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Abstract Hyponatremia (plasma sodium concentration or
P[Na
?]\136 mEq/L) is the most common electrolyte
unbalance in clinical practice. Although it constitutes a
negative prognostic factor, it frequently remains under-
diagnosed and undertreated. Tolvaptan is an oral V2-re-
ceptor antagonist which produces aquaresis. Given its
emerging role in the treatment of dilutional hyponatremia,
we aimed to compare the efficacy and safety of two dif-
ferent doses of this drug in an Emergency Department (ED)
setting. Consecutive patients with moderate–severe euv-
olemic or hypervolemic hyponatremia were sequentially
assigned to the 15 mg Group and to the 7.5 mg Group, and
were revaluated at 6, 12 and 24 h. Further evaluations and
administrations were scheduled daily until P[Na
?] correc-
tion was achieved or the maximum period of 72 h was
exceeded. A 1-month follow-up was performed. Twenty-
three patients were enrolled: 12 were included in the 15 mg
Group, 11 in the 7.5 mg Group. Both doses significantly
elevated the P[Na
?] over 24 h, although the 15 mg Group
showed faster corrections than the 7.5 mg Group (12 vs
6 mEq/L/24 h; P = 0.025). An optimal correction rate
(within 4–8 mEq/L/24 h) was observed in 45.4 % of the
7.5 mg Group against 25.0 % (P n.s.). The standard dose
led to dangerous overcorrections ([12 mEq/L/24 h) in
41.7 % of the patients, while the low dose did not cause
any (P = 0.037). No osmotic demyelination syndrome was
observed. A 7.5 mg tolvaptan dose can be considered both
effective and safe in treating hyponatremia in the ED,
while a 15 mg dose implicates too high risk of
overcorrection.
Introduction
Hyponatremia is defined as a plasma sodium concentration
(P[Na
?]) below 136 mEq/L; it can be classified as mild
(130–135 mEq/L), moderate (125–129 mEq/L) and severe
(\125 mEq/L) [1]. Its prevalence amounts to 15–30 % of
hospitalized patients [2], 7 % of whom are affected by
moderate–severe forms [3]. Hyponatremia primarily
affects the elderly [4, 5] mostly as a chronic disorder,
present in about 7–11 % of outpatients [6].
Hyponatremia is often underestimated and undertreated:
17 % of 3087 patients included in the Hyponatremia
Registry received no treatment, and about 75 % were dis-
charged still hyponatremic [7].
When the P[Na
?] is particularly low, or the disease
develops in less than 48 h (acute hyponatremia), the
osmotic gradient between brain cells and plasma induces
cerebral edema. During chronic hyponatremia, brain cells
compensate their transient hypertonicity preventing cere-
bral edema and maintaining the patient asymptomatic [8].
Hyponatremia represents an independent negative prog-
nostic factor and predictor of mortality; it is still unclear
whether hyponatremia reflects the severity of the under-
lying disorder, or plays an active role in increasing
mortality [9], costs of hospitalization and readmission
rates [10]. It is well known that even mild chronic
hyponatremia is associated with unapparent adverse
events such as gait instability and attention deficit [11];
therefore, treating hyponatremic patients is actually con-
sidered mandatory regardless of the absolute value of the
P[Na
?].
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Although hyponatremia often develops during hospital-
ization (the incidence being up to 15 %) [12], it has been
estimated that about 15–20 % of the patients admitted to
the Emergency Department (ED) are already hyponatremic
[13].
The correct approach to hyponatremia needs to be
addressed as to the identification of its pathophysiologic
mechanism. According to the patient’s volume status,
hyponatremia is classified as hypovolemic, euvolemic and
hypervolemic [1, 14]. The precise correct diagnosis
improves the clinical outcome [15, 16], since hypovolemic
hyponatremia is properly treated by infusing Na? in large
volumes of fluid (i.e., normal saline, 0.9 % NaCl), while
the most targeted treatment of fluid overload hyponatremia
is the elimination of the water excess (aquaresis) [17].
Aquaresis can be obtained using V2-receptor antagonists,
the vaptans, which block arginine-vasopressin (AVP)-de-
pendent water reabsorption in the collecting ducts. AVP is
deeply involved in the pathogenesis of hyponatremia due to
fluid overload observed in chronic heart failure (CHF) or
advanced hepatic cirrhosis, both characterized by an
inappropriate AVP secretion [18, 19].
Tolvaptan is an oral selective V2-receptor antagonist
approved in the US for the treatment of dilutional
hyponatremia. The SALT trials demonstrate both efficacy
and safety of a 15 mg starting dose [20]. Many studies
demonstrate tolvaptan efficacy in long-term treatments [21]
and in many specific diseases such as: CHF [22–24],
SIADH [25], or autosomal dominant polycystic kidney
disease [26].
The FDA indicates tolvaptan as a therapeutic option for
hospitalized symptomatic hyponatremic patients resistant
to fluid restriction or for asymptomatic hyponatremic
patients with a P[Na
?]\125 mEq/L [27]. Limited data are
available on the use of tolvaptan in severe hyponatremia:
few subjects enrolled in the SALT trials had a
P[Na
?]\125 mEq/L, while a P[Na
?]\120 mEq/L in
presence of neurological alterations constituted an exclu-
sion criterion [20].
Infusions of hypertonic fluid boluses remain the gold
standard treatment in patients with severe symptomatic
hyponatremia (coma, dizziness, cardio-respiratory distress)
[13].
No efficacy and safety data on tolvaptan in severe
asymptomatic hyponatremia are available; on this basis, we
wanted to investigate whether tolvaptan could be, in the
ED, a valuable option as first therapeutic choice in
hyponatremic patients, unless hypovolemic or presenting
severe symptoms, regardless of the P[Na
?] at admission.
The latest review of the Literature set the optimal range
of correction at 4–8 mEq/L/24 h, and the safe upper limit
at 12 mEq/L/24 h [28]; in fact, previous studies show that a
correction of about 4–6 mEq/L over 24 h can usually
remove all symptoms, [29] and a correction rate B12 mEq/
L/24 h is associated with a negligible risk of osmotic
demyelination syndrome (ODS).
We aimed to identify the most appropriate starting dose
selecting between the standard dose of 15 mg and a lower
dose of 7.5 mg. This halved dose has been recently studied
with encouraging results among selected subgroups of
patients, [30, 31] and has been suggested to be a safer
option for the treatment of paraneoplastic SIADH [32].
Methods
The study was designed as a non-randomized open-label
trial, approved by the local Ethics Committee of the
Maggiore della Carita` University Hospital in Novara (CE
125/10, October 22nd, 2010). Consecutive patients affected
by moderate-to-severe hyponatremia (P[Na
?]\130 mEq/
L) admitted to the ED from April 2012 to June 2015 were
evaluated to assess their volume status by using a clinical
algorithm based on recent medical history, physical
examination and laboratory findings. Hypovolemia was
determined by the presence of at least three of these cri-
teria: vomiting, diarrhea, fever, hypotension, tachycardia,
dry mucosae, dry axillary skin, positive pinch test, cold
extremities, small pulse and thirst. Hypervolemia was
assessed by the presence of at least two among peripheral
edema, distended jugular veins, abdomino jugular reflux,
wet lung sounds, serous effusions and a P[Cl
-]/P[Na
?]
between 0.716 and 0.784 [33]. Normovolemic and hyper-
volemic patients were considered eligible for this trial.
Exclusion criteria were age\18 years, acute hypona-
tremia (i.e., hyponatremia for less than 48 h), clinical
hypovolemia, presence of severe symptoms (seizures, deep
drowsiness or a Glasgow Coma Score\9), acute coronary
syndrome, respiratory distress, major trauma, stroke,
shock, hyperglycemia (blood glucose[250 mg/dL),
chronic kidney disease (eGFR\ 30 mL/min), or lack of
informed consent.
The study was carried out in the ED Observation Unit of
the Novara University Hospital. The maximum study per-
iod was set at 72 h.
Each patient received the first tolvaptan dose, and was
evaluated after 6, 12 and 24 h by collecting data helpful in
establishing water and Na? balance (such as urine output,
weight, plasma and urine electrolytes concentration). In
order to keep a negative water balance, patients underwent
a controlled regimen of fluid intake. Drugs potentially
responsible for hyponatremia were withdrawn.
When required, further evaluations and further tolvaptan
administrations were scheduled every 24 h until a P[Na
?]




Patients were consecutively assigned to two different
tolvaptan daily doses (15 or 7.5 mg). Since tolvaptan
(Samsca) is only available in 15 and 30 mg tablets, the
Pharmaceutical Service of the Maggiore della Carita`
Hospital cut 15 mg tablets in half in order to obtain the low
tolvaptan dose. When the P[Na
?] correction was obtained,
asymptomatic patients attended an educational program
and were discharged. A telephonic follow-up was sched-
uled 1 month later.
If the P[Na
?] did not improve and the clinical conditions
of the patients tended to deteriorate, an infusion of 2 mL/
kg of hypertonic saline solution (3 % NaCl) was performed
as a rescue treatment. Patients with less severe symptoms
but still hyponatremic or presenting other clinical problems
at the end of the study, were admitted to the appropriate
hospital ward (usually Internal Medicine).
Patients presenting overcorrection withdrew tolvaptan
therapy, were encouraged to increase water intake, and
were clinically observed in order to exclude neurological
impairment during the next hours.
In order to establish efficacy and safety of the two
tolvaptan doses, we used the increase in P[Na
?] (DP[Na
?])
over 24 h to define four different correction categories
[28]:
• low degree of correction:\4 mEq/L/24 h;
• optimal correction: 4–8 mEq/L/24 h;
• mild (or low risk) overcorrection: 9–12 mEq/L/24 h;
• severe (or high risk) overcorrection:[12 mEq/L/24 h.
The primary efficacy endpoints were to evaluate the
ability of a low tolvaptan dose to obtain a statistically
significant increase in the P[Na
?] with respect to baseline
values, and to compare the efficacy of the two tolvaptan
doses. Secondary endpoints related both to efficacy and
safety. The correction kinetics were used to evaluate the
percentage of patients who experienced correction rates
within the optimal range [28]. Subjects were also divided
into two subgroups according to their baseline P[Na
?] by
setting a cut-off at 120 mEq/L. Correction rates between
subgroups were then compared.
Clinically relevant adverse events were recorded, and
the correction kinetics was used to determine the occur-
rence of overly rapid correction.
Before discharge, patients were given an educational
program about diet, fluid intake and correct use of diuretics
in order to prevent the relapse of hyponatremia.
Each patient was asked to check his P[Na
?] 30 days
after tolvaptan withdrawal, and was then contacted by
telephone for a structured interview to detect symptoms or
adverse events.
Statistical analysis were performed using the MedCalc
software v12.5.0 (MedCalc software bvba—Ostend, Bel-
gium). Continuous data were analyzed through the Mann–
Whitney U test, while the two-tailed Fisher’s exact text
was used to analyze categorical data. Statistical signifi-
cance was set at P\0.05.
Results
We enrolled 23 hyponatremic patients from April 2012 to
June 2015. The median age was 76 (63–91), 17 subjects
were women (73.9 %), 18 (78.3 %) received diuretic
treatment, 20 (87.0 %) took at least 4 drugs daily and 12
(52.2 %) were affected by at least 3 active chronic dis-
eases. At ED admission, 11 patients (47.8 %) showed signs
or symptoms attributable to hyponatremia as summarized
in Table 1; the remaining 12 were asymptomatic on ED
evaluation, and their hyponatremia was occasionally found
while dealing with different clinical pictures (mostly acute
heart failure). Moreover 7 subjects (30.4 %) had a baseline
P[Na
?]\120 mEq/L.
The first 12 patients recruited received a standard
tolvaptan dose (15 mg Group), while the next 11 were
treated with a low dose (7.5 mg Group). The two groups
had comparable median P[Na
?] (125 vs 124 mEq/L) and
comparable median ages (77 vs 76 years, P value n.s. for
both). In the 15 mg Group, 66.7 % of the patients were
females, 83.3 % were under diuretic therapy and 91.7 %
took at least 4 different drugs daily, against 81.8, 72.7
and 81.8 %, respectively, of the other group. Tables 2
and 3 show the comparisons of baseline data between
groups.
Only 1 patient in the 15 mg Group (8.2 %) required a
second tolvaptan administration, while 7 patients (63.6 %)
in the 7.5 mg Group (63.6 %) took at least two doses; 2
patients (18.2 %) in the low dose group took tolvaptan for
three consecutive days and 1 of them failed to achieve a
P[Na
?] correction within 72 h. This latter patient, as well
as another one, required hospitalization; all the remaining 9
patients were discharged. In the 15 mg Group, 3 patients
(25.0 %) were hospitalized, although P[Na
?] correction
had been already obtained, because of heart failure, pneu-
monia and multiple myeloma. Table 4 shows the total
cumulative tolvaptan dose and the cumulative duration of
therapy in the ED for the two groups.
Given the high number of patients who successfully
corrected their P[Na
?] within the first 24 h in the 15 mg
Group, we focused our analysis on the first 24 h.
Twenty-four hours after tolvaptan administration, the
median P[Na
?] was 132 mEq/L in the 15 mg Group (min
126 mEq/L, max 139 mEq/L) and 130 mEq/L in the
7.5 mg (min 111 mEq/L, max 135 mEq/L). A statistically
significant difference was observed between median
P[Na
?] at baseline and after 24 h in both 15 and 7.5 mg
Groups (P = 0.0004 and P = 0.011, respectively).
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The difference between the serial P[Na
?] measurements
with respect to the baseline P[Na
?] was defined as DP[Na
?]
and was used to describe the correction kinetics after
tolvaptan administration (Fig. 1):
• at 6 h the DP[Na?] was 3 mEq/L (min 1 mEq/L, max
12 mEq/L) in the 15 Group and 2 mEq/L (min
-1 mEq/L, max 7 mEq/L) in the 7.5 mg Group
(P = 0.158);
• at 12 h the DP[Na?] was 9 mEq/L (min 3 mEq/l, max
21 mEq/L) in the 15 mg Group and 4 mEq/L (min
1 mEq/L, max 12 mEq/L) in the 7.5 mg Group
(P = 0.042);
• at 24 h the DP[Na?] was 12 mEq/L (min 6 mEq/L, max
25 mEq/L) in the 15 mg Group and 6 mEq/L (min
1 mEq/L, max 11 mEq/L) in the 7.5 Group
(P = 0.025).
Table 1 Percentage frequencies of signs and symptoms potentially related to the hypotonic state induced by hyponatremia
Signs and symptoms of hyponatremia 7.5 mg 15 mg P value
Yes (%) No (%) Missing data (%) Yes (%) No (%) Missing data (%)
Confusion or drowsiness 18.2 81.8 0 8.3 91.7 0 0.590
Disorientation in time, place or person 9.1 90.9 0 8.3 91.7 0 1.000
Cognitive-motor slowing 36.4 63.6 0 8.3 91.7 0 0.155
Subjective dizziness 36.4 54.5 9.1 8.3 91.7 0 0.135
Gait instability ± falls 27.3 63.6 9.1 16.7 83.3 0 0.624
Abdominal pain 18.2 72.7 9.1 0 100 0 0.195
Nausea ± vomiting 18.2 72.7 9.1 16.7 83.3 0 1.000
Headache 9.1 81.8 9.1 8.3 91.7 0 1.000
Fatigue or general malaise 18.2 72.7 9.1 8.3 91.7 0 0.571
No statistically significant difference emerged in the frequency of these findings between the two groups
Table 2 Medians and interquartile range of the main continuous variables evaluated before tolvaptan administration in the two treatment groups
Continuous variable 7.5 mg 15 mg P value
Age (years) 76 [IQR 65–83] 77 [IQR 73–82] 0.424
Systolic arterial blood pressure (mmHg) 130 [IQR 119–160] 138 [128–149] 0.877
Diastolic arterial blood pressure (mmHg) 75 [IQR 61–88] 78 [IQR 68–85] 1.000
Mean arterial blood pressure (mmHg) 90.00 [IQR 82.73–116.67] 97.50 [IQR 90.84–101.67] 0.782
Heart rate (bpm) 66 [IQR 61–78] 86 [IQR 72–93] 0.009
Body temperature (C) 36.0 [IQR 35.7–36.4] 36.0 [IQR 36.0–36.6] 0.261
Weight (kg) 59.0 [IQR 42.0–69.0] 63.8 [IQR 38.8–82.5] 0.248
BMI (kg/m2) 24.32 [IQR 17.98–29.31] 25.38 [IQR 22.44–29.77] 0.413
Blood glucose (mg/dL) 120 [IQR 100–143] 151 [IQR 96–227] 0.491
P[Cr] (mg/dL) 0.76 [IQR 0.60–0.85] 0.88 [IQR 0.78–1.01] 0.207
P[Na
?] (mEq/L) 124 [IQR 119–128] 125 [IQR 118–127] 0.951
P[Cl
-] (mEq/L) 92 [IQR 86–97] 91 [IQR 86–94] 0.355
P[K
?] (mEq/L) 4.5 [IQR 4.1–5.1] 4.2 [IQR 3.7–4.5] 0.196
U[Cr] (mg/dL) 51.6 [IQR 31.0–92.0] 38.4 [IQR 17.6–73.7] 0.320
U[Na
?] (mEq/L) 55 [IQR 35–88] 66 [IQR 32–81] 0.887
U[Cl
-] (mEq/L) 72 [IQR 36–99] 64 [IQR 37–88] 1.000
U[K
?] (mEq/L) 29.3 [IQR 21.4–66.6] 24.6 [IQR 15.0–38.1] 0.286
FENa? % 0.42 [IQR 0.25–1.05] 1.25 [IQR 0.31–2.21] 0.166
P[Cl
-]/P[Na
?] 0.76 [IQR 0.73–0.76] 0.74 [IQR 0.71–0.76] 0.306
Apart from the isolated exception of heart rate, statistically significant differences were not observed in the medians of these parameters between
the two groups
BMI body mass index, P[Cr] plasma creatinine concentration, P[Na
?] plasma sodium concentration, P[Cl
-] plasma chloride concentration,
P[K
?] plasma potassium concentration, U[Cr] urine creatinine concentration, U[Na
?] urine sodium concentration, U[Cl
-] urine chloride con-
centration, U[K
?] urine potassium concentration, FENa? fractional Na? excretion
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The faster correction rates observed in the 15 mg Group
were accompanied by a larger urine output over the 24-h
period (Fig. 2a, b): the median daily urine output was
4000 mL (min 1550 mL, max 9750 mL) in this group,
compared to 2000 mL (min 1100 mL, max 3100 mL) in
the 7.5 mg Group (P = 0.014).
In the 15 mg Group, the comparison of the 24-h DP[-
Na?] between patients with a baseline P[Na
?]\120 mEq/
L and patients with a baseline P[Na
?] C120 mEq/L
showed a clear difference (20 vs 8 mEq/L/24 h) that,
however, did not reach full statistical significance
(P = 0.053). The same trend was observed in the 7.5 mg
Group, but the difference was smaller (8 vs 4 mEq/L/24 h;
P = 0.156) (Fig. 3).
Considering the median values of the DP[Na
?] obtained
24 h after tolvaptan administration, the 7.5 mg Group
shows a median correction rate of 6 mEq/L/24 h, perfectly
included within the optimal range (4–8 mEq/L/24 h), while
the 15 mg Group has a higher median correction rate
(12 mEq/L/24 h).
In the 15 mg Group only 25.0 % of patients showed
optimal correction rates, compared to 45.4 % in the 7.5
Group (P = 0.400). None of the patients in the standard
dose group experienced a low degree of correction (DP[-
Na?]\4 mEq/L/24 h), against 27.3 % of the low dose
group. Correction rates[8 mEq/L/24 h were observed in
75.0 % of the patients in the 15 mg Group and in 27.3 % in
the 7.5 mg Group.
By splitting again this latter category, it is possible to
separate those patients who did not achieve an optimal
correction rate (DP[Na
?] within 9 and 12 mEq/L/24 h)
Table 3 Percentage frequencies of the main categorical variables investigated at the moment of the volume assessment
Categorical variable 7.5 mg 15 mg P value
Yes (%) No (%) Missing data (%) Yes (%) No (%) Missing data (%)
Protracted vomiting ([3 episodes/h) or
protracted diarrhea ([10 episodes/die)
0 100 0 8.3 91.7 0 1.000
External body temperature[38 C
in the previous 48 h
0 100 0 16.7 83.3 0 0.478
Bedridden 18.2 81.8 0 16.7 83.3 0 1.000
Thirst 36.4 63.6 0 41.7 58.3 0 1.000
Hypotension (SABP)\100 mmHg) 0 100 0 0 100 0 1.000
Orthostatic hypotension 0 81.8 18.2 0 75.0 25.0 0.471
Tachycardia (HR[100 bpm)
and/or raise in the HR in
orthostatism[30 bpm
0 100 0 8.3 91.7 0 1.000
Dry mucosae 18.2 81.8 0 50.0 50.0 0 0.193
Positive pinch test 0 100 0 25.0 75.0 0.217
Dry axillary skin 0 100 0 0 100 0 1.000
Small pulse 9.1 90.9 0 8.3 91.7 0 1.000
Cold extremities 9.1 90.9 0 25.0 75.0 0 0.590
Distended neck veins 9.1 90.9 0 50.0 50.0 0 0.069
Abdominojugular reflux 9.1 90.9 0 8.3 91.7 0 1.000
Peripheral edema 27.3 72.7 0 66.7 33.3 0 0.100
Wet lung sounds 9.1 90.9 0 16.7 83.3 0 1.000
Pleural effusion 9.1 90.9 0 16.7 83.3 0 1.000
Ascites 0 100 0 8.3 91.7 0 1.000
0.715\ P[Cl
-]/P[Na
?]\ 0.785 81.8 9.1 9.1 58.3 41.7 0 0.162
Elements strongly consistent with dehydration or hypovolemia (hypotension or orthostatic hypotension) were found in none of the patients in the
two groups. Some of them showed physical evidences of water excess (peripheral edema, distended neck veins). Apart from the isolated
exception of distended neck veins, no statistically significant difference was observed in the distribution of the findings given in this table be-
tween the two groups
H hours, SABP systolic arterial blood pressure, HR heart rate, P[Na
?] plasma sodium concentration, P[Cl
-] plasma chloride concentration
Table 4 Tolvaptan cumulative dose administered during the study
period and cumulative duration of therapy in the ED in the two groups
Group 7.5 mg 15 mg
Tolvaptan cumulative dose (mg) 13.64 16.25
Cumulative duration of therapy (h) 43.64 26.00
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from those who actually experienced an overcorrection
(DP[Na
?][12 mEq/L/24 h), thus commuting the efficacy
analysis into a safety analysis. None of the patients in the
7.5 mg Group exceeded 12 mEq/L/24 h, against 41.7 % in
the 15 mg Group (P = 0.037) (Fig. 4).
The 1-month follow-up results are available for 19
patients (82.6 %): 1 patient in the 7.5 mg Group and 3
patients in the 15 mg Group were lost to follow-up. All
patients of the low dose group were still alive 30 days after
the end of the study and their median P[Na
?] was
137 mEq/L. Three patients treated with 15 mg died during
the follow-up period, but their deaths were related neither
to hyponatremia nor to tolvaptan treatment (1 patient died
because of respiratory failure and 2 because of heart fail-
ure). The 6 remaining patients of this group were available
for the follow-up interview and showed a median P[Na
?] of
136 mEq/L at 30 days. The statistical analysis of the
1-month mortality did not show a significant difference
between the two groups.
Discussion
Hyponatremia is the most frequent electrolyte disorder
observed in clinical practice. Its prevalence in ED patients
is probably 15–20 % [13]. Even though it is associated
with poor outcome and prolonged hospitalization [9]
hyponatremia is currently underdiagnosed and undertreated
in the ED worldwide. In the last 10 years many studies
have demonstrated efficacy and safety of vaptans in treat-
ing patients with hypervolemic and normovolemic
hyponatremia [20, 34–37]; none of them was carried out in
the ED. Actually, two different meta-analysis involving a
large number of clinical trials on different vaptans show
little effect of these drugs in increasing the P[Na
?] and no
effect on mortality [38, 39].
With this pilot study we intended to investigate efficacy
and safety of two tolvaptan doses in treating hyponatremic
patients in the ED.
Out of the 23 hyponatremic patients we enrolled, 12
received the standard tolvaptan daily dose of 15 mg while
11 received an halved dose.
Fig. 1 The graph compares the increase in P[Na
?] at each revaluation
time (6, 12 and 24 h) from baseline values between patients treated
with the standard dose (light bars) and patients treated with the low
dose (dark bars). The difference between the two groups reached
statistic significance 12 h after tolvaptan administration and was still
significant at the end of the 24-h period. DP[Na
?] = difference
between the P[Na
?] measured at each revaluation and the P[Na
?]
measured at baseline
Fig. 2 a The graph represents the time courses of the P[Na
?] in the
two groups during the first 24 h of treatment. Despite a similar rapid
rise until 6 h after tolvaptan administration, the patients treated with
15 mg kept an higher correction rate throughout the remaining 18 h
of therapy thus reaching an higher final P[Na
?] than those who
received the low dose (7.5 mg). b The graph represents the time
course of urine output in the two groups during the first 24 h of
treatment. The larger diuresis observed in the 15 mg Groups reflects
the higher correction rate described in Fig. 2a and is substantially
consistent with the dose-dependent aquaretic effect of tolvaptan
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Our results confirm the efficacy of the standard tolvap-
tan dose and, as expected on the basis of the report of the
Hyponatremia Registry and of other retrospective studies
[7, 40], the median P[Na
?] increase we found was sub-
stantially higher compared to those described in the SALT
trials [20]. All patients treated with the standard tolvaptan
dose showed an increase in the P[Na
?] of at least 6 mEq/L
in the first 24 h, with a median increase in the P[Na
?] of
12 mEq/L. Although the correction rates observed in this
group exceeded the values recommended by recent
guidelines in 75.0 % of patients [13, 28], we observed no
ODS; this is in line with the results of many trials and
retrospective investigations in which vaptans-related ODS
were not observed [13]. Nevertheless, experimental animal
models of chronic hyponatremia have demonstrated that
these drugs can induce the same changes in osmotic gra-
dients and encephalic damages (including ODS) produced
by improper infusive therapies [41]. This remarks the
importance of a careful use of vaptans in this setting since
the risk of ODS actually exists, and the lack of vaptans-
related ODS might be explained by the recent awareness of
safer correction rates, and by the knowledge that the
P[Na
?] should be promptly re-lowered in patients experi-
encing overly rapid corrections.
Tolvaptan ability in increasing the P[Na
?] is also con-
firmed with the 7.5 mg dose, but the correction rate is
lower compared to the standard dose; though apparently
predictable, this observation is partially in conflict with a
very recent retrospective study that reports similar mean
daily correction rates with the two doses (9.8 ± 2.9 vs
9.9 ± 3.9 mEq/L) [41]. This study was focused on con-
secutive patients affected by SIADH and treated with
tolvaptan; however, all the 6 patients treated with 7.5 mg
presented with severe hyponatremia, and this characteristic
could fully explain their higher correction rates.
In our study, about 90 % of the patients treated with
7.5 mg show an increase in the P[Na
?] of at least 3 mEq/L/
Fig. 3 Patients with lower P[Na
?] at baseline exhibit higher correc-
tion rates than those starting from less hyponatremic values. The
difference between the two subgroups was near borderline signifi-
cance in the 15 mg Group. In the 7.5 mg Group this trend is
substantially confirmed, but the difference is smaller and P value is
further from statistical significance
Fig. 4 In the 7.5 mg Group 45.4 % of the patients have a correction
rate within the optimal range of 4–8 mEq/L/24 h while in the 15 mg
Group only 25.0 % of the patients meet this criterion of effectiveness.
A low degree of correction is observed in 27.3 % of the patients
treated with the low dose, while none of the patients who received the
standard dose have a correction rate\4 mEq/L/24 h. In the 7.5 mg
Group, 27.3 % of the patients showed correction rates exceeding the
upper limit of the optimal range (low risk overcorrection), compared
to 33.3 % of the other group. No high risk overcorrection was
observed in patients treated with the low dose, while in the 15 mg
Group 41.7 % experienced correction rates[12 mEq/L/24 h. How-
ever, none of them developed an ODS
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24 h, while the median rise in the P[Na
?] observed in the
first 24 h is 6 mEq/L (min 1 mEq/L, max 11 mEq/L), and
the percentage of patients who obtain an optimal correction
rate (4–8 mEq/L) is 45.4 %.
Only 1 patient failed to achieve a P[Na
?] of at least
130 mEq/L during the 72-h period. It should not be con-
sidered a treatment failure because the starting P[Na
?] was
102 mEq/L and after 72 h the P[Na
?] was 114 mEq/L; in
the case of such a severe chronic hyponatremia, a mean
daily rise in the P[Na
?] of 4 mEq/L/24 h is both adequate
and safe, and is consistent with Literature’s recommenda-
tions [28].
Interestingly, we observed differences in the correc-
tion kinetics depending on the baseline P[Na
?]. Patients
with lower starting P[Na
?] had the tendency to experi-
ence faster correction rates than patients with higher
starting P[Na
?]. Our observations are completely in line
with an assumption already described both for traditional
and for tolvaptan treatments: the lower the P[Na
?] is at
baseline, the higher tends to be the correction rate
[20, 29, 40].
We observed a significant reduction in the occurrence of
overcorrections in patients treated with 7.5 mg compared
to the standard dose both with the conventional cut-off of
12 mEq/L/24 h (0.0 vs 41.7 %) and with the more
restrictive one of 8 mEq/L/24 h (27.3 vs 75.0 %).
Although no severe adverse event was observed in our
patients, we believe that, in the ED, a starting tolvaptan
dose of 7.5 mg is safer considering that patients are
heterogeneous and often affected by multiple comorbidities
and under multi-drug therapies; moreover, much important
information, such as the time of onset of hyponatremia and
the normal body weight, are often unavailable or unreli-
able. Additionally, the superiority of the halved dose in
terms of safety is even clearer in patients with severe
hyponatremia, who are those at the highest risk to develop
ODS after overly rapid corrections.
As shown in Table 4, the duration of treatment in 15 mg
Group is significantly shorter compared to 7.5 mg Group;
this difference could be misleading since it reflects the high
incidence of overcorrection observed in 15 mg Group, and
demonstrates the safer correction kinetics obtained with the
low dose.
The main limitation of this work is the lack of ran-
domization and the unblinded design. Moreover, the cri-
teria used to select eligible patients were essentially
clinical, and no instrumental analysis was carried out to
confirm the patients’ volume status. However, the study
aimed to evaluate the potential role of tolvaptan in the
treatment of hyponatremia in the ED, where the first
evaluation of patients necessarily relies on essential clinical
parameters and on a few readily and widely available
laboratory tests.
In conclusion, the data presented in this study demonstrate
that a 7.5 mg tolvaptan dose can be considered an effective
and safe alternative to infusive therapy as first approach to
euvolemic and hypervolemic hyponatremia in an ED setting.
On the other hand, our results raise concerns about safety of
the 15 mg tolvaptan dose as first therapeutic approach in
patients presenting hyponatremia, as it implicates an high risk
of overly rapid correction. The main future developments of
our findings would concern the possibility to discharge low
risk patients with the prescription of a home low dose
tolvaptan therapy and a close revaluation. This therapeutic
strategy needs to be associated with a correct information
about water intake and a careful revision of home therapy. In
our opinion it could eventually reduce hospitalizations and,
hopefully, costs, as it would allow us to treat in a simple way a
large number of cases of a widespread and insidious disease
that, according to the Literature, still remains frequently
untreated.
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